Page No.:

RECEIVED CENTRAL FAX CENTER

FEB 15 2008

## Amendment to the Claims:

Amend Claims 8, 11, 14, 17, and 20.

## **Listing of Claims:**

A compound of structural formula I: 1. (original)

$$R_2$$
 $R_2$ 
 $R_2$ 
 $R_2$ 
 $R_1$ 
 $R_1$ 
 $R_2$ 
 $R_3$ 
 $R_4$ 

wherein:

each n is independently 0, 1, 2, or 3;

W is selected from the group consisting of CH2, CHF, and CF2;

X is selected from the group consisting of S, S(O), S(O)2, CH2, CHF, and CF2;

Y and Z are each independently selected from the group consisting of O, S, N, and NR<sup>7</sup>, with the proviso that at least one of Y and Z is N;

R<sup>1</sup> is hydrogen or cyano;

R<sup>2</sup> is selected from the group consisting of

hydrogen,

halogen,

cyano,

hydroxy,

C1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens,

C1-6 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens,

(CH<sub>2</sub>)<sub>n</sub>-COOH,

Page No.:

(CH<sub>2</sub>)<sub>n</sub>-COOC<sub>1-6</sub> alkyl, (CH<sub>2</sub>)<sub>n</sub>-CONR<sup>3</sup>R<sup>4</sup>, (CH<sub>2</sub>)<sub>n</sub>-NR<sup>3</sup>R<sup>4</sup>, (CH<sub>2</sub>)<sub>n</sub>-NR<sup>6</sup>SO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>-NR<sup>6</sup>CONR<sup>3</sup>R<sup>4</sup>, (CH<sub>2</sub>)<sub>n</sub>-NR<sup>6</sup>COR<sup>6</sup>, (CH<sub>2</sub>)<sub>n</sub>-NR<sup>6</sup>CO<sub>2</sub>R<sup>5</sup>,

(CH<sub>2</sub>)<sub>n</sub>-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, CO<sub>2</sub>H,

C<sub>1-6</sub> alkyloxycarbonyl, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, wherein any methylene (CH<sub>2</sub>) carbon atom in R<sup>2</sup> is independently unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkyl unsubstituted or substituted with one to five halogens;

R<sup>3</sup> and R<sup>4</sup> are independently selected from the group consisting of

hydrogen,

(CH2)n-phenyl,

(CH2)n-C3-6 cycloalkyl, and

C<sub>1-6</sub> alkyl,

wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; or

R<sup>3</sup> and R<sup>4</sup> together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C<sub>1-6</sub> alkyl, and

C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

each  $R^5$  is independently selected from the group consisting of  $(CH_2)_n$ -phenyl,  $(CH_2)_n$ - $C_3$ -6 cycloalkyl, and  $C_{1-6}$  alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy,  $C_{1-6}$  alkyl, and  $C_{1-6}$  alkoxy,

Case No.: 214
Page No.: 4

wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and wherein any methylene (CH2) carbon atom in R<sup>5</sup> is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkyl unsubstituted or substituted with one to five halogens;

each R6 is hydrogen or R5; and

R<sup>7</sup> is selected from the group consisting of

hydrogen,

(CH<sub>2</sub>)<sub>n</sub>-phenyl,

(CH<sub>2</sub>)<sub>n</sub>-C<sub>3-6</sub> cycloalkyl, and

.C<sub>1-6</sub> alkyl,

wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C<sub>1-6</sub> alkyl, and C<sub>1-6</sub> alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens.

2. (original) The compound of Claim 1 wherein the carbon atom marked with an \* has the stereochemical configuration as depicted in formula IIa:

$$R_2$$
 (IIa)

3. (original) . The compound of Claim 1 of structural formula IIb:

Page No.: 5

$$R_2$$
 (IIb)

4. (original) The compound of Claim 3 wherein X is CH2, CHF, or CF2 and R<sup>1</sup> is hydrogen.

5. (original) The compound of Claim 3 wherein the carbon atom marked with an \* has the stereochemical configuration as depicted in formula IIc:

$$R_2$$
 (IIc)

and wherein X is CH2, CHF, or CF2 and R1 is hydrogen.

6. (original) The compound of Claim 1 of structural formula Id:

$$H_2N$$
 $N$ 
 $X$ 
 $R_2$ 
(IId)

Page No.: 6

7. (original) The compound of Claim 6 wherein X is CH2, CHF, or CF2 and R<sup>1</sup> is hydrogen.

8. (amended) The compound of Claim 6 wherein the carbon atom marked with an \* has the stereochemical configuration as depicted in formula IIe:

$$R_2$$
 (IIe)

wherein X is CH2, CHF, or CF2 and R<sup>1</sup> is hydrogen.

9. (original) The compound of Claim 1 of structural formula IIf:

$$R_2$$
 $R_2$ 
 $R_2$ 
 $R_2$ 
 $R_3$ 
 $R_4$ 
 $R_4$ 
 $R_5$ 
 $R_7$ 
 $R_7$ 
 $R_7$ 
 $R_7$ 
 $R_7$ 

10. (original) The compound of Claim 9 wherein X is CH2, CHF, or CF2 and R1 is hydrogen.

11. (amended) The compound of Claim 9 wherein the carbon atom marked with an \* has the stereochemical configuration as depicted in formula IIg:

Page No.: 7

$$H_2N_{1,1}$$
 $X$ 
 $N$ 
 $X$ 
 $R_2$ 
(IIg)

wherein X is CH2, CHF, or CF2 and R1 is hydrogen.

12. (original) The compound of Claim 1 of structural formula IIh:

$$H_2N$$
 $N$ 
 $X$ 
 $R_1$ 
 $X$ 
 $R_2$ 
(IIIh)

13. (original) The compound of Claim 12 wherein X is CH2, CHF, or CF2 and R1 is hydrogen.

14. (amended) The compound of Claim 12 wherein the carbon atom marked with an \* has the stereochemical configuration as depicted in formula IIi:

$$R_2$$
 $R_2$ 
 $R_3$ 
 $R_4$ 
 $R_1$ 
 $R_2$ 
 $R_3$ 
 $R_4$ 
 $R_5$ 
 $R_7$ 
 $R_7$ 

Page No.: 8

wherein X is CH2, CHF, or CF2 and R1 is hydrogen.

15. (original) The compound of Claim 1 of structural formula IIj:

16. (original) The compound of Claim 15 wherein X is CH2, CHF, or CF2 and R<sup>1</sup> is hydrogen.

17. (amended) The compound of Claim 15 wherein the carbon atom marked with an \* has the stereochemical configuration as depicted in formula IIk:

wherein X is CH2, CHF, or CF2 and R1 is hydrogen.

18. (original) The compound of Claim 1 of structural formula III:

Page No.: 9

$$R^{7}N$$
 $R_{2}$ 
 $R_{2}$ 
 $R_{1}$ 
 $R_{2}$ 
 $R_{3}$ 
 $R_{4}$ 
 $R_{5}$ 
 $R_{5}$ 
 $R_{6}$ 
 $R_{7}$ 
 $R_{7}$ 

19. (original) The compound of Claim 18 wherein X is CH2, CHF, or CF2 and R1 is hydrogen.

20. (amended) The compound of Claim 18 wherein the carbon atom marked with an \* has the stereochemical configuration as depicted in formula IIm:

$$H_2N$$
,  $*$ 
 $NR^7$ 
 $N$ 
 $R_2$ 
(Ilm)

wherein X is CH2, CHF, or CF2 and R1 is hydrogen.

21. (original) A pharmaceutical composition which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.

## 22. (cancelled)

23. (original) A method for treating non-insulin dependent (Type 2) diabetes in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of Claim 1.

24-31. (cancelled)